Head-to-head comparison
| Property | PT-141 | Kisspeptin-10 |
|---|---|---|
| Category | Sexual Health | Sexual Health |
| Legal Status | Prescription | Research Only |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~2.7 hours | ~28 minutes |
| Mol. Weight | 1,025.18 Da | 1,302.41 Da |
| Side Effects | Nausea (40%), Flushing (20%), Headache | Injection site discomfort, Hot flashes, Abdominal discomfort |
Key differences
- Mechanism: PT-141 activates melanocortin-4 receptors (MC4R) in the brain to directly stimulate sexual arousal; kisspeptin-10 activates KISS1R receptors on GnRH neurons to stimulate the HPG axis and downstream sex hormone production.
- FDA status: PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women; kisspeptin-10 is not FDA-approved and is used primarily as a research and diagnostic tool.
- Effect type: PT-141 produces acute arousal and desire effects within 45 minutes; kisspeptin-10 affects the hormonal cascade (LH, FSH, testosterone/estrogen) with more gradual effects.
- Route: PT-141 is administered subcutaneously; kisspeptin-10 is administered subcutaneously or intravenously.
- Primary research populations: PT-141 has been studied in both men and women; kisspeptin-10 research has focused on reproductive endocrinology, including infertility diagnostics and hypothalamic amenorrhea.
- Side effects: PT-141 commonly causes nausea (40%), flushing, and headache; kisspeptin-10 is generally well tolerated in clinical studies with minimal reported side effects.
The verdict
PT-141 and kisspeptin serve different roles in sexual health. PT-141 is a direct arousal agent with FDA approval and established clinical evidence for HSDD. Kisspeptin-10 operates upstream at the hormonal regulation level and is more relevant to reproductive endocrinology and fertility research. For acute libido enhancement, PT-141 has stronger clinical evidence; for hormonal axis optimization, kisspeptin is the more targeted peptide.
Frequently asked questions
PT-141 does not directly increase testosterone. It works through melanocortin receptors in the brain to stimulate sexual arousal independently of sex hormone levels. Kisspeptin-10, by contrast, stimulates the HPG axis and can increase LH and downstream testosterone production.
Yes, PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It was approved in June 2019. Kisspeptin-10 is not FDA-approved.
They act through different pathways—PT-141 via melanocortin receptors and kisspeptin via the GnRH/HPG axis. No clinical studies have evaluated this combination. The mechanisms are distinct but the interaction profile is not well characterized.
PT-141 has FDA approval specifically for female HSDD and published clinical trial data demonstrating efficacy. Kisspeptin-10 research in women has focused primarily on reproductive endocrinology (fertility, menstrual disorders) rather than sexual desire. For desire-related dysfunction, PT-141 has more direct clinical evidence.
PT-141 produces arousal effects within approximately 45 minutes of subcutaneous injection. Kisspeptin-10 affects the HPG hormonal cascade with LH rises detectable within 30–60 minutes, but the downstream effects on sexual function are more gradual and less acutely perceptible.